Overall, we demonstrate that inhibition of histone methyltranferase EZH2 regulates cell fate decisions in response to genotoxic chemotherapy in multi-drug resistant models of B-cell lymphoma. This evidence concerns the gene EZH2 and B-cell non-Hodgkin lymphoma.